WLWeijin Lu

Weijin Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weijin Lu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Dongmei Zhang

    State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Jinan University, Guangzhou, China

    1 shared publication
  • Minfeng Chen

    State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China

    1 shared publication
  • Wen-Cai Ye

    State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Jinan University, Guangzhou 510632, P. R. China

    1 shared publication
  • Xiaobo Li

    College of Pharmacy, Jinan University, No. 601, Huangpu Road West, Guangzhou 510632, China

    1 shared publication
  • Yong Li

    College of Pharmacy, Jinan University, No. 601, Huangpu Road West, Guangzhou 510632, China

    1 shared publication

Latest Publications

  • Open Access

    The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

    by Xiaobo Li, Yong Li, Weijin Lu, Minfeng Chen, Wencai Ye, Dongmei Zhang

    Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.